The purpose of this study is to test whether propranolol is capable of reducing subsequent physiological trauma-related conditioned responses, as well as self-reported post-traumatic stress disorder (PTSD) symptoms.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
76
1mg per Kg (participant weight)
After completing the double-blind phase of the study, participants will receive short acting propranolol 1mg/kg (patient weight) + long acting propranolol (1 or 1.5 mg/kg) followed by memory reactivation. Dose level for the long-acting propranolol will be randomly assigned across participants.
Douglas Mental Health University Institute
Verdun, Quebec, Canada
RECRUITINGElectromyogram
Time frame: Two weeks post-treatment
Heart rate
Time frame: Two weeks post-treatment
Skin conductance
Time frame: Two weeks post-treatment
PTSD symptom levels
PTSD symptom levels will be assessed 2 to 26 weeks after randomization
Time frame: 2 to 26 weeks
Quality of life
Quality of life assessments will be conducted 2 to 26 weeks following randomization
Time frame: 2 to 26 weeks
Memory Experience
The Memory Experiences Questionnaire will be administered from 2 to 26 weeks following randomization
Time frame: 2 to 26 weeks
Psychophysiological assessments
Psychophysiological assessments will be repeated 26 weeks following randomization
Time frame: 26 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.